Hjem › Kastringsresistent prostatakræft › Californien
Kastringsresistent prostatakræft kliniske forsøg i Californien
11 studier for Kastringsresistent prostatakræft søger deltagere på steder i Californien.
Byer i Californien
Officiel studietekst (engelsk)
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- MemorialCare Orange Coast Medical Center, Fountain Valley
- University Of California San Diego, La Jolla
- Cancer and Blood Specialty Clinic, Los Alamitos
- og 6 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07225946A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- University of California at San Diego, La Jolla
- Cedars Sinai Medical Center, Los Angeles
- Ronald Reagan UCLA Medical Center, Los Angeles
- og 1 flere
RekruttererFase 3
Alder 18 og opefter · Mænd · Opdateret 25. sep. 2026 · NCT07164443A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
- START Los Angeles, Los Angeles
RekruttererFase 1
Alder 18 og opefter · Mænd · Opdateret 24. sep. 2026 · NCT07719361A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- UCLA Hematology & Oncology ( Site 0003), Los Angeles
- University of California-Irvine Medical Center ( Site 0016), Orange
- UCSF Medical Center at Mission Bay ( Site 0034), San Francisco
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 17. sep. 2026 · NCT06863272Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
- UCSD Moores Cancer Center ( Site 0039), La Jolla
- UCLA Hematology/Oncology - Santa Monica ( Site 0044), Los Angeles
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 17. sep. 2026 · NCT06353386Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
- UCI Health Chao Family Comprehensive Cancer Center, Orange
- Investigational Site Number: 403, Palo Alto
RekruttererFase 1
Alder 18 og opefter · Mænd · Opdateret 10. sep. 2026 · NCT05997615Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- USC Norris Comprehensive Cancer Center, Los Angeles
- UCLA Department of Medicine, Los Angeles
- Hoag Memorial Hospital Presbyterian, Newport Beach
- og 2 flere
RekruttererFase 1
Alder 18 til 100 · Mænd · Opdateret 13. aug. 2026 · NCT05519449A Study of MGC026 in Participants With Advanced Solid Tumors
- The Angeles Clinic and Research Institute, Los Angeles
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 11. aug. 2026 · NCT06242470A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
- Stanford Cancer Center, Palo Alto
RekruttererFase 1
Alder 18 og opefter · Mænd · Opdateret 10. aug. 2026 · NCT0606784164Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
- Stanford Cancer Institute, Stanford
RekruttererFase 1/2
Alder 18 og opefter · Mænd · Opdateret 6. maj 2026 · NCT0486860418F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
- VA Greater Los Angeles Healthcare System, Los Angeles
RekruttererFase 4
Alder 18 og opefter · Mænd · Opdateret 27. nov. 2024 · NCT06706921Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.